ArticleOncoimmunology2013
The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Mechanisms of Oncolytic Virus-Induced Multi-Modal Cell Death and Therapeutic Prospects.International journal of molecular sciences · 2025Review
- Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming.International journal of molecular sciences · 2025Review
- Synthetic RIG-I-Agonist RNA Induces Death of Hepatocellular Carcinoma Cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2025Article
- Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.Cancer immunology, immunotherapy : CII · 2024Article
- HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response.Viruses · 2021Review
- Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium.Lasers in medical science · 2021Article
- CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.Molecular therapy oncolytics · 2021Article
- An Analysis Regarding the Prognostic Significance of MAVS and Its Underlying Biological Mechanism in Ovarian Cancer.Frontiers in cell and developmental biology · 2021Article
- Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids.Immunity · 2020Review
- Latent Membrane Protein 1 of Epstein-Barr Virus Promotes RIG-I Degradation Mediated by Proteasome Pathway.Frontiers in immunology · 2018Article
- Stress responses from the endoplasmic reticulum in cancer.Frontiers in oncology · 2015Review
- Tumor suppressor activity of RIG-I.Molecular & cellular oncologyReview
- Trial Watch:: Oncolytic viruses for cancer therapy.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A replication-incompetent hemagglutinating virus of Japan (HVJ) envelope (HVJ-E) induces apoptosis selectively in cancer cells. Fragments of the viral RNA genome transported by HVJ-E are recognized by retinoic acid-inducible gene I (RIG-I) and mitochondrial antiviral signaling (MAVS). Specific pro-apoptotic factor are selectively upregulated in cancer cells downstream of the RIG-I/MAVS pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.